Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse.
Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.
Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee and represents Pew as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
When compounded drugs are created in large volumes and shipped across the country, as was the case with injections linked to the national meningitis outbreak, producers should meet some of the same quality assurance requirements as drug manufacturers. Read More
Pew and other health care organizations released a report exploring measures that should be considered to address the ongoing issue of drug shortages in the United States, which impacts lifesaving medicines including antibiotics, chemotherapy, and cardiovascular drugs. Read More
A closer look at the stakeholder requirements for the Drug Supply Chain Security Act as defined by Title II of the act. Requirements are broken down by each segment of the supply chain: manufacturers, re-packagers, wholesale distributors and dispensers. Read More